Cargando…

Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review

Tuberculosis (TB) is a common infectious disease that is present all around the world. This insidious disease needs drastic measures for its eradication. One of the actions contributing to it is the timely diagnosis and offering suitable treatment options for latent tuberculosis patients. In this re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahid, Noor ul ain, Naguit, Noreen, Jakkoju, Rakesh, Laeeq, Sadia, Reghefaoui, Tiba, Zahoor, Hafsa, Yook, Ji Hyun, Rizwan, Muneeba, Mohammed, Lubna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205649/ https://www.ncbi.nlm.nih.gov/pubmed/35733481 http://dx.doi.org/10.7759/cureus.25083

Ejemplares similares

Some Twist of Molecular Circuitry Fast Forwards Overnight Sleep Hours: A Systematic Review of Natural Short Sleepers' Genes
por: Yook, Ji Hyun, et al.
Publicado: (2021)

Is Acupuncture Safe and Effective Treatment for Migraine? A Systematic Review of Randomized Controlled Trials
por: Naguit, Noreen, et al.
Publicado: (2022)

Efficacy of Behavioural Intervention, Antipsychotics, and Alpha Agonists in the Treatment of Tics Disorder in Tourette’s Syndrome
por: Rizwan, Muneeba, et al.
Publicado: (2022)

Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis
por: Rockwood, Neesha, et al.
Publicado: (2015)

Correction: Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis
Publicado: (2015)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
por: Li, Tsung-Lun, et al.
Publicado: (2021)

Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
por: Zheng, Xiao-Fu, et al.
Publicado: (2020)

Deciphering the late steps of rifamycin biosynthesis
por: Qi, Feifei, et al.
Publicado: (2018)

Study on Dissolution Thermodynamics and Cooling Crystallization of Rifamycin S
por: Chen, Kui, et al.
Publicado: (2021)

Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent
por: Hanh, Bui Thi Bich, et al.
Publicado: (2020)

Generation of Tetracycline and Rifamycin Resistant Chlamydia Suis Recombinants
por: Marti, Hanna, et al.
Publicado: (2021)

Stability of Non-Ionic Surfactant Vesicles Loaded with Rifamycin S
por: Marchianò, Verdiana, et al.
Publicado: (2022)

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting
por: Pease, Christopher, et al.
Publicado: (2021)

House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study
por: Chang, Alicia H, et al.
Publicado: (2013)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance
por: Lan, Tian, et al.
Publicado: (2022)

Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins
por: Ganapathy, Uday S., et al.
Publicado: (2023)

Draft Genome Sequence of the Rifamycin Producer Amycolatopsis rifamycinica DSM 46095
por: Saxena, Anjali, et al.
Publicado: (2014)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.
por: Strolin Benedetti, M, et al.
Publicado: (1994)

Integrative metagenomic and biochemical studies on rifamycin ADP-ribosyltransferases discovered in the sediment microbiome
por: Shin, Jae Hong, et al.
Publicado: (2018)

Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics
por: Dyavar, Shetty Ravi, et al.
Publicado: (2020)

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus
por: Paulowski, Laura, et al.
Publicado: (2022)

State of the Art on Developments of (Bio)Sensors and Analytical Methods for Rifamycin Antibiotics Determination
por: Noor, Hassan, et al.
Publicado: (2023)

An in silico analysis of rpoB mutations to affect Chlamydia trachomatis sensitivity to rifamycin
por: Benamri, Ichrak, et al.
Publicado: (2022)

Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
por: Oscanoa, Teodoro J., et al.
Publicado: (2023)

Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers’ diarrhoea: reply
por: Steffen, Robert, et al.
Publicado: (2019)

8-Deoxy-Rifamycin Derivatives from Amycolatopsis mediterranei S699 ΔrifT Strain
por: Ye, Feng, et al.
Publicado: (2020)

Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein
por: Harbottle, John, et al.
Publicado: (2021)

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
por: Philipose, Jobin, et al.
Publicado: (2022)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Draft Genome Sequence of Rifamycin Derivatives Producing Amycolatopsis mediterranei Strain DSM 46096/S955
por: Singh, Priya, et al.
Publicado: (2014)

A feedback regulatory model for RifQ-mediated repression of rifamycin export in Amycolatopsis mediterranei
por: Lei, Chao, et al.
Publicado: (2018)

Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism
por: Peek, James, et al.
Publicado: (2018)

Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4pqcevrtt7bc7lkvj1hk0h4602